COPD Flashcards
Short-acting Beta Agonist
Common indications
- COPD- releive breathlessness brought on by exercise
- Asthma- used in conjunction with other agents
- Hyperkalaemia- nebulised salbutamol may be used in conjunction with other treatments for the urgent treatment of hyperkalaemia
B2-agonist MOA
- B2-receptors are found on the smooth muscle of the bronchi, GIT, uterus and blood vessels
- Stimulation of the GPCR activates a signalling cascade that leads to the relaxation of smooth muscle
- Improves airflow reduce SOB
- B2-agonist stimulates Na/K/ATPase pumps on the cell surface
- Shifting K into the cell- useful for hyperkalaemia
B2-Agonist important side effects
- Tachycardia
- Palpitations
- Anxiety
- Tremor
- Increase serum glucose levels- diabetes
- Muscle cramps
B2-agonist
Warnings
- Only use LABA in asthma if there is an ICS treatment used as well
- Without the steroid there is an increase mortality rate
- Care should be given to people with CVD
- Tachycardia= worsen angina, provoke arrhythmias
- Especially important when using as part of the hyperkalaemia treatment
B2-agonist important interactions
- Beta blockers- may reduce the effectiveness of the agonist
- Extensive use of B2 with ICS and theophylline may lead to hypokalaemia monitor U&E
B2- agonist
Monitoring + advise
- Symptom severity
- Peak flow meter
- Spirometry
- Exacerbations
- Tell patients this will help there breathing (symptoms) but not treat/cure the disease.
- If they need to use B2-agonist regularly then they need to get there other inhalers stepped up
- Make sure they clean their inhaler regularly
ICS
Common indications
- Asthma- treat airway inflammation and control symptoms at step 2 of asthma therapy when SABA fails
- COPD- to control symptoms and prevent exacerbations in patients who have severe airflow obstruction on spirometry and or recurrent exacerbations
- Can be used in combination with LABA + LAMA
ICS
Mechanism of action
- Corticosteroids pass through the plasma membrane and interact with receptors in the cytoplasm
- The activated receptor then passes into the nucleus to modify transcription of a large number of genes
- Pro-inflammatory cytokines, interleukins and chemokines are downregulated
- While anti-inflammatory proteins are upregulated
- In the airways this reduces mucosal inflammation, widens the airways and reduces mucus secretion
- Improves symptoms
ICS
Important adverse events
- Immunosupressive effect in the mouth increases risk of oral thrush
- Hoarse voice
- In COPD, they can increase the risk of pneumonia
- Very little is absorbed into the blood, so there are few systematic adverse effect unless very high doses are used
ICS
Warnings
- High doses- use in caution in COPD patients with a history of pneumonia
- Children- growth suppression
Antimuscarinic bronchodilators
Common indications
- Asthma
- COPD
Antimuscarinic bronchodilators
MOA
- Antimuscarinic drugs bind to the muscarinic receptors, where they act as a competitive inhibitor of acetylcholine
- Stimulation of the muscarinic receptors brings about a wide range of parasympathetic rest and digest effects
- In blocking the receptor, antimuscarinic have the opposite effect
- Reduce smooth muscle tone
- Reduce secretion from glands in the respiratory and GIT
- Relaxation of pupillary constrictor, ciliary muscles preventing accommodation in the eye
Antimuscarinic bronchodilators
Adverse effects
- When antimuscarinic bronchodilators are taken by inhalation, there is relatively little systematic absorption
- Adverse effects, apart from dry mouth are uncommon
Antimuscarinic bronchodilators
Warnings
- Antimuscarinics should be used with caution in patients susceptible to angle-closure glaucoma, in whom they can precipitate a dangerous rise in intraocular pressure
- They should be used with caution in patients with or at risk of arrhythmias
- However, in practice, most patients can take these drugs by inhalation without major problems
Antimuscarinic bronchodilators
Corticosteroids (Glucocorticoids) systemic
Common indications
- Allergic or inflammatory disorders- anaphylaxis and asthma COPD
- Only use in COPD on advise of a specialist
- Suppression of autoimmune disease e.g. inflammatory bowel disease, inflammatory arthritis
- In the treatment of some cancers as part of chemotherapy or to reduce tumour-associated swelling
- Hormone replacement in adrenal insufficiency or hypopituitarism
Corticosteroids (Glucocorticoids) systemic
MOA
- These corticosteroid exert mainly glucocorticoid effects
- They bind to cytosolic glucocorticoid receptors, which then translocate to the nucleus and bind to glucocorticoid-response elements, which regulate gene expression
- Corticosteroids are most commonly prescribed to modify the immune response
- They upregulate anti-inflammatory genes
- Down regulate pro-inflammatory proteins
- Direct actions on inflammatory cells include suppression of circulating monocytes and eosinophils
- Their metabolic effects include increased gluconeogenesis from increased circulating amino and fatty acids, released by catabolism (breakdown) of muscle and fat
- These drugs also have a mineralocorticoid effects, stimulating Na+ and water retention and K+ excretion in the renal tubles
Corticosteroids (Glucocorticoids) systemic
Important adverse effects
- Immunosuppression increases the risk and severity of the infection and alters the host response
- Metabolic effects include diabetes mellitus (gluconeogenesis)and osteoporosis
- Increased catabolism causes proximal muscle weakness, skin thinning with easy bruising and gastritis
- Mood and behavioural changes- insomnia, confusion, psychosis and suicidal ideas
- Hypertension, hypokalaemia, oedema can result from mineralocorticoid action
-
Corticosteroid treatment suppresses the pituitary adrenocorticotropic hormone (ACTH) secretion, switching off stimulus for normal adrenal cortisol production
- In prolonged treatment, this causes adrenal atrophy- preventing endogenous cortisol secretion
- If corticosteroids are abruptly withdrawn suddenly, an acute Addisonian crisis with cardiovascular collapse may occur
- Withdraw slowly and allow recovery of adrenal function
- Symptoms of chronic glucocorticoid deficiency that occur during treatment withdrawal include fatigue, weight loss and arthralgia
Corticosteroids (Glucocorticoids) systemic
Warnings
- Corticosteroids should be prescribed with caution in people with infection- worsening of infection
- And in Children- growth suppression
Corticosteroids (Glucocorticoids) systemic
Interactions
- Corticosteroids increase the risk of peptic ulceration and GI bleeding when used with NSAIDs
- Enhance hypokalaemia in patients taking B2-agonists, theophylline, loop or thiazide diuretics
- Their efficacy may be reduced by CYP P450 inducers (Carbamazepine, phenytoin, rifampicin)
- Corticosteroids reduce the immune response to Vaccines
Corticosteroids (Glucocorticoids) systemic
Administration + Communication
- OD corticosteroid treatment should be taken in the morning to mimic the natural circadian rhythm and reduce insomnia
- State to patients that treatment should suppress the underlying disease process and that the patient will usually start to feel better within 1-2 days
- For patients who require prolonged treatment, warn then NOT to stop treatment suddenly as this could make them very unwell
- Give them a steroid card to carry with them at all times and show if they need treatment
- Discuss longer-term risk: diabetes, osteoporosis + bone fractures
- Patients on long term won’t be able to increase secretion in response to stress so should always carry steroids around with them